Table 5.
Condition-specific evaluation of the KDIGO guidelines by providers treating subtypes of NSa
| SSNS (n = 19) | SRNS (n = 16) | MCD (n = 23) | FSGS (n = 24) | MN (n = 27) | |
|---|---|---|---|---|---|
| Do guidelines reflect current management of specific condition | |||||
| Not at all consistent | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) | 0 (0%) |
| Somewhat consistent | 14 (74%) | 14 (88%) | 13 (57%) | 16 (67%) | 17 (63%) |
| Completely consistent | 5 (26%) | 2 (13%) | 10 (43%) | 6 (25%) | 10 (37%) |
| Guidelines are acceptable | 11 (58%) | 12 (70%) | 17 (77%) | 17 (71%) | 20 (77%) |
| If not acceptable, why? (Individual counts) | |||||
| Difference in prescribing practices from recommendations | 3 | 4 | 2 | 3 | 1 |
| Availability of recommended therapeutic agents | 4 | 1 | 0 | 0 | 2 |
| Concerns about efficacy of recommended therapy | 4 | 3 | 2 | 4 | 4 |
| Concerns about side effects of recommended therapy | 5 | 4 | 5 | 5 | 5 |
| Patient characteristics (comorbidity, older adults, ethnicity, etc.) | 2 | 3 | 3 | 3 | 3 |
| Patient/family preference | 3 | 0 | 1 | 1 | 1 |
n is the number of providers who cared for the disease subtype where SSNS is steroid-sensitive nephrotic syndrome.
SRNS, steroid resistant nephrotic syndrome; MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy.
aNot all providers cared for all disease subtypes.